CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today announced the appointment of Andrew Robert Branagan, MD, PhD, to its Board of Advisors. Dr. Branagan brings extensive expertise in hematologic malignancies, immunology, and the development of novel therapeutic strategies, including cellular therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806825904/en/

Dr. Andrew Branagan, MD, PhD Clinical Investigator at Massachusetts General Hospital and Assistant Professor at Harvard Medical School, newly appointed to CGT Global’s Board of Advisors.

Dr. Branagan is currently a Clinical Investigator and Medical Director at Massachusetts General Hospital (MGH), as well as Assistant Professor of Medicine (Hematology Oncology) at Harvard Medical School. He also serves on the Cellular Therapy Steering Committee at MGH. Since 2018, Dr. Branagan has also served as a CGT Global Medical Director and will now assume the dual role of Board Advisor.

"We are thrilled to welcome Dr. Andrew Branagan to our Board of Advisors," said Cate Spears, CEO and Founder of CGT Global. "His profound understanding of the human immune system, particularly in the context of plasma cell disorders like multiple myeloma and Waldenstrom's macroglobulinemia, combined with his direct experience in clinical trials of advanced therapies, will be invaluable as we advance our cell and gene therapy pipeline. His ongoing research into mechanisms of resistance to CAR-T cell therapy underscores his commitment to pushing the boundaries of what's possible for patients."

Dr. Branagan's distinguished career includes a PhD in Investigative Medicine from Yale University, where he studied novel vaccination strategies to enhance immune responses and reduce infections in patients with blood cancers. He has also served on numerous scientific advisory boards for pharmaceutical companies focused on oncology.

"I am honored to join the Board of Advisor at CGT Global at such a pivotal time for cell and gene therapy," said Dr. Branagan. "The potential of these innovative modalities to transform patient care is immense, and I look forward to contributing my expertise in clinical development, immunology, and hematologic oncology to help guide CGT Global in its mission to bring life-changing therapies to patients in need."

Dr. Branagan is board-certified in Internal Medicine, Medical Oncology, and Hematology. He focuses on developing novel immune-based cancer therapies, medical education, and global health. He is also an active member of several professional organizations, including the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Working Group, Waldenstrom’s Macroglobulinemia Clinical Trial Network, and Deylight Foundation, where he contributes to establishing international consensus on patient care.

About CGT Global

CGT Global is a biotechnology leader accelerating access to life-changing cell and gene therapies. Through its national footprint of clinical sites and laboratories, CGT Global delivers high-quality biospecimens, GMP-compliant manufacturing, and end-to-end clinical trial support and patient care to drive therapeutic breakthroughs and expand patient access. Headquartered in Folsom, CA, CGT Global partners with top pharmaceutical companies, CROs, and hospitals. Learn more at www.cgt.global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250806825904/en/